'김갑성' 기자의 전체기사
-
Antengene Announces XPOVIO® Approved in China for the Se…
- This approval for XPOVIO® in combination with bortezomib and dexamethasone (XVd) for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy marks the third approved indication of the drug in China.- XPOVIO® as a monotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) and in combination with dexamethasone in patients with R/R MM, two of the three approved indications of XPOVIO® in China, have already been included into China's National Reimbursement Drug List.- Results from the BENCH study
- 김갑성 기자
- 2025-07-28 18:49
-
Interventional Robot's RCT Research Published in JNIS, a Le…
SHANGHAI, July 28, 2025 -- The multicenter, randomized controlled trial (RCT) results of the PANVIS-A® NeuroInterventional Robotic System—led by Professor Liu Jianmin (Changhai Hospital) in collaboration with Professor Sun Jun (Wenzhou Central Hospital), Professor Chen Wenhuo (Zhangzhou Municipal Hospital of Fujian Province), and Professor Cheng Guangsen (Zhuhai People's Hospital)—have been officially published in the Journal of NeuroInterventional Surgery (JNIS). This milestone marks the first time a China-developed vascular-interventional robot has gained recognition from a premier inte
- 김갑성 기자
- 2025-07-28 18:35
-
Embolx Launches Sniper G3: Revolutionizing Embolization w…
SUNNYVALE, Calif., July 28, 2025 -- Embolx, a leader in advanced microcatheters for targeted embolization procedures, today announced the release of its next-generation Sniper G3 Balloon Occlusion Microcatheter. This third iteration of the innovative device delivers significant enhancements, including an extended shelf life, improved ease of use, and streamlined preparation, directly addressing critical feedback from physician users. The highly anticipated Sniper G3 features a 24-month shelf life, doubling the longevity of its predecessor. This improvement offers greater invent
- 김갑성 기자
- 2025-07-28 18:00
-
Caliway Announces FDA Clearance of IND Application for CBL-…
CBL-514, Caliway's first-in-class lipolysis drug candidate, has been granted clearance from the U.S. FDA to proceed with SUPREME-01, a global, multicenter, pivotal Phase 3 study. Subject recruitment is expected to begin in the U.S. and Canada in Q3 2025. CBL-514 is the first 505(b)(1) investigational drug with FDA clearance to proceed with a Phase 3 study for the proposed indication of "Reduction of Abdominal Subcutaneous Fat." Caliway also plans to submit regulatory applications for its second global pivotal Phase 3 study, SUPREME-02, in the U.S., Canada, and Australi
- 김갑성 기자
- 2025-07-28 17:51
-
Precision Orthopedic Surgery in Asia: Addressing Regiona…
TAIPEI, July 28, 2025 -- The Malaysian Orthopedic Association (MOA), Aclub Taiwan, and A Plus Biotechnology Corporation Limited will co-host a high-level academic conference on August 3, 2025, at Sunway Medical Centre in Kuala Lumpur, bringing together orthopedic professionals from across Asia to explore the latest advances in personalized, minimally invasive orthopedic surgery. The event will feature both in-person and online participation options. As Asia's active population grows and patient expectations evolve, the demand for personalized, minimally invasive orthopedic solu
- 김갑성 기자
- 2025-07-28 17:32
-
HCSA Community Services and Tan Tock Seng Hospital Sign M…
SINGAPORE, July 28, 2025 -- In celebration of the World Hepatitis Day (28 July), HCSA Community Services and Tan Tock Seng Hospital (TTSH), an anchor hospital of NHG Health, today signed a Memorandum of Understanding (MoU) to reinforce their shared commitment to eliminating Hepatitis C (HCV) among former drug offenders in Singapore, the World Health Organization's global strategy of eliminating Hepatitis C. This marks a significant step towards the Educate, Test, Treat! (ETT) initiative, launched in 2022 with the funding support of Gilead Sciences. Witnessed by Mdm Rahayu Mahza
- 김갑성 기자
- 2025-07-28 16:11
-
Successful Completion of First CRS with HIPEC on a 60-year-old W…
KOLKATA, India, July 28, 2025 -- In a landmark achievement, a 60-year-old woman with advanced primary peritoneal carcinomatosis was successfully treated with Cytoreductive Surgery (CRS) combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at Manipal Hospital Dhakuria, under the expertise of Dr. Ashutosh Daga, Medical Oncologist, and Dr. Sagnik Ray, Surgical Oncologist. The 12-hour long procedure adds a milestone in cancer care treatment. The sexagenarian was initially taken to another hospital where she was misdiagnosed as a case of chronic liver failure with ascites
- 김갑성 기자
- 2025-07-28 15:20
-
Plasmatreat Introduces HydroPlasma®: 高性能表面洗浄における持続…
ドイツ・シュタインハーゲン, 2025年7月26日 -- 大気圧プラズマ技術の世界的リーダーであるPlasmatreat GmbHは、ガラスや金属表面を超高精度で洗浄する革新的かつ環境に優しいソリューションHydroPlasma®を発表しました。Openair-Plasma®の実証された効果とイオン化水の反応力を組み合わせた HydroPlasma®は、指紋、油分、塩分、グリースなどの頑固な有機・無機汚染物を化学薬品を使わずに除去する新たな基準を打ち立てます。 ハイテク産業とプロセスにおける洗浄の革命 自動車、電子機器、航空宇宙、医療機器製造などの分野では、微細な汚染物でさえ、接着、コーティング、印刷、シーリングといった重要な工程での密着性を損なう可能性があります。従来の洗浄方法は溶剤や湿式化学処理に頼ることが多いですが、HydroPlasma® は圧縮空気、電気、水のみを使用し、化学薬品を使わない持続可能な代替手段を提供します。この先進技術は、洗浄効率を高めるだけでなく、環境に配慮した生産活動も支援します。 HydroPlasma®の仕組み：科学と持続可能性の融合 HydroPlasma®の特許取得済みプロセ
- 김갑성 기자
- 2025-07-28 15:03
-
플라스마트리트, 하이드로플라스마® 출시… 고성능 표면 세척 위한 지속 가능한 신기술
슈타인하겐, 독일, 2025년 7월 26일 -- 대기 플라스마 기술 분야의 글로벌 선도 기업 플라스마트리트 유한책임회사(Plasmatreat GmbH)가 유리 및 금속 표면의 초정밀 세척을 위한 혁신적이고 친환경적인 솔루션 하이드로플라스마(HydroPlasma®)를 출시했다. 오픈에어 플라스마(Openair-Plasma®)의 검증된 효능에 이온화된 물의 반응성을 결합한 하이드로플라스마®는 지문, 기름, 염분, 그리스 등 제거가 까다로운 유기 및 무기 오염 물질을 화학 약품 없이 제거함으로써 세정 기술의 새로운 기준을 제시하고 있다. 하이테크 산업 및 공정의 세정 혁신 자동차, 전자, 항공우주, 의료 제조 등 다양한 산업 분야에서는 미세한 오염 물질조차도 접착, 코팅, 인쇄, 밀봉 등 주요 공정에서 접착력에 영향을 줄 수 있다. 기존 세정 방식은 일반적으로 용제나 습식 화학 처리에 의존해 왔으나 하이드로플라스마®는 압축 공기, 전기, 물만을 사용해 화학 물질 없이 지속 가능한 대안을 제공한다. 이 첨단 기술은 세정 효율을 높이는 동시에 친환경적인
- 김갑성 기자
- 2025-07-28 15:03
-
Alteogen Receives Positive CHMP Opinion for Aflibercept Biosim…
[ 메디채널 김갑성 기자 ] CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing EYLUXVI® to the reference product Eylea® Upon approval, EYLUXVI® will be Alteogen's second biosimilar product, following a Herceptin® biosimilar by Alteogen's license partner Qilu Pharmaceutical DAEJEON, South Korea, July 28, 2025 -- Alteogen Inc. (KOSDAQ:196170) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for EYLUXVI® (code name: ALT-L9), a bi
- 김갑성 기자
- 2025-07-28 14:00
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-10-20_MON
- CARsgen Presents Preliminary Results on Satri-cel for Adjuvant Therapy of Pancreatic Cancer at ESMO Congress 2025 08:15
- Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Once-Monthly Subcutaneous Depot Treatment Formulation of Small Molecule GLP-1R Agonist ASC30 for Obesity 08:10
- ESMO 2025: CStone Discloses Phase I Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) 08:10
- Leading Competition Economist Dr. Luke Wainscoat Joins The Brattle Group 07:25
- Clover Appoints Nicholas Jackson, Ph.D., as President of Global R&D and Alliances 07:00
- Webull Reduces Minimum ASX Trading Fee To $1 06:00
- Yaber Expands Its Global Footprint -- Now Available at JB Hi-Fi Across Australia 05:00
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 10월 20일 09시 40분